echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sanofi's new indication for Duplizumab is about to be approved

    Sanofi's new indication for Duplizumab is about to be approved

    • Last Update: 2021-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 23, the official website of NMPA showed that the application for the new indication of Sanofi Priyuumab has entered the administrative examination and approval stage, or it will be approved in the near future


    Dupilumab is a human monoclonal antibody developed by Sanofi that targets IL-4Rα


    In March 2017, Duplizumab was approved by the FDA to become the first targeted biologic drug for the treatment of moderate to severe atopic dermatitis in adults.


    On June 17, 2020, Duplizumab was approved in China for the treatment of moderate to severe atopic dermatitis in adults


    From the Insight database (http://db.


    Atopic dermatitis is a common recurrent, chronic inflammatory skin disease.


    According to the EvaluatePharma report, Dupixent will become a key driving force for Sanofi’s future growth.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.